Iminopyrimidinones: A novel pharmacophore for the development of orally active renin inhibitors

Iminopyrimidinones: A novel pharmacophore for the development of orally active renin inhibitors The P1 N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin Discovery of benzimidazole derivatives as orally active renin inhibitors: Optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors Design and optimization of renin inhibitors: Orally bioavailable alkyl amines Optimization of orally bioavailable alkyl amine renin inhibitors Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo Potential virtual lead identification in the discovery of renin inhibitors: Application of ligand and structure-based pharmacophore modeling approaches (Phosphinyloxy)acyl amino acid inhibitors of angiotensin converting enzyme (ACE). 1. Discovery of (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline, a novel orally active inhibitor of ACE